ReviewJournal of the National Cancer Institute2021

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.

Mithunah Krishnamoorthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.